ImmuPharma Investor Relations Material
Latest events
H1 2025
6 Aug, 2025
H2 2024
19 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImmuPharma plc
Access all reports
ImmuPharma plc is a pharmaceutical company focused on the research, development, and commercialization of novel peptide-based drugs. The company specializes in therapies for autoimmune and inflammatory diseases, with activities spanning early-stage discovery through to clinical development. Its research is supported by collaborations with scientific institutions and licensing partnerships. The company is headquartered in London, United Kingdom, and its shares are listed on the AIM.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
IMM
Country
🇬🇧 United Kingdom